{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:34:20Z","timestamp":1790408060612,"version":"4.1.0"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T00:00:00Z","timestamp":1549238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Epileptic seizures are frequent in patients with glioblastoma, and anticonvulsive treatment is often necessary. While clinical guidelines recommend all approved anticonvulsants, so far it is still unclear which of the available drugs is the best therapeutic option for treating glioma-associated seizures, also in view of possible anti-tumorigenic effects. In our study, we employed four patient-derived low-passage cell lines of glioblastoma and three cell lines of brain metastases, and challenged these cultures with four anticonvulsants with different mechanisms of action: levetiracetam, valproic acid, carbamazepine and perampanel. Cell proliferation was determined by bromodeoxyuridine incorporation. To further analyze the effects of perampanel, apoptosis induction was measured by caspase 3\/7 activation. Glutamate release was quantified and glucose uptake was determined using <jats:sup>18<\/jats:sup>F-fluorodeoxyglucose. Real-time polymerase chain reaction was employed to assess the expression of genes associated with glutamate release and uptake in brain tumor cells. Of the four anticonvulsants, only perampanel showed systematic inhibitory effects on cell proliferation, whereas all other anticonvulsants failed to inhibit glioma and metastasis cell growth <jats:italic>in vitro<\/jats:italic>. Metastasis cells were much more resistant to perampanel than glioblastoma cell lines. Glucose uptake was attenuated in all glioblastoma cells after perampanel exposure, whereas cell death via apoptosis was not induced. Extracellular glutamate levels were found to be significantly higher in glioblastoma cell lines as compared to metastasis cell lines, but could be reduced by perampanel exposure. Incubation with perampanel up-regulated glutamine synthetase expression in glioblastoma cells, whereas treatment with valproic acid and levetiracetam downregulated excitatory amino acid transporter-2 expression. Overall, our data suggest that perampanel acts as an anticonvulsive drug and additionally mediated anti-tumorigenic effects.<\/jats:p>","DOI":"10.1371\/journal.pone.0211644","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T18:36:36Z","timestamp":1549305396000},"page":"e0211644","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":89,"title":["AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8782-5205","authenticated-orcid":true,"given":"Falko","family":"Lange","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"We\u00dflau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Porath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max Frederik","family":"H\u00f6rnschemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Bergner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd Joachim","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2296-2027","authenticated-orcid":true,"given":"Christina Susanne","family":"Mullins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Linnebacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"K\u00f6hling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Kirschstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,2,4]]},"reference":[{"issue":"5","key":"pone.0211644.ref001","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1474-4422(07)70103-5","article-title":"Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management","volume":"6","author":"MS van Breemen","year":"2007","journal-title":"Lancet Neurol"},{"issue":"2","key":"pone.0211644.ref002","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3171\/2009.2.JNS081132","article-title":"Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. Clinical article","volume":"111","author":"KL Chaichana","year":"2009","journal-title":"J Neurosurg"},{"issue":"11","key":"pone.0211644.ref003","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/neuonc\/nop045","article-title":"Symptoms and problems in the end-of-life phase of high-grade glioma patients","volume":"12","author":"EM Sizoo","year":"2010","journal-title":"Neuro-Oncol"},{"issue":"6","key":"pone.0211644.ref004","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/neuonc\/nov269","article-title":"Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy","volume":"18","author":"TS Armstrong","year":"2016","journal-title":"Neuro-Oncol"},{"issue":"9","key":"pone.0211644.ref005","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S1470-2045(12)70266-8","article-title":"Epilepsy meets cancer: when, why, and what to do about it?","volume":"13","author":"M Weller","year":"2012","journal-title":"Lancet Oncol"},{"key":"pone.0211644.ref006","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/B978-0-12-802997-8.00016-5","article-title":"Epilepsy and brain tumors","volume":"134","author":"DJ ENGLOT","year":"2016","journal-title":"Handb Clin Neurol"},{"issue":"4","key":"pone.0211644.ref007","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2016.26","article-title":"Seizures and gliomas\u2014towards a single therapeutic approach","volume":"12","author":"G Huberfeld","year":"2016","journal-title":"Nat Rev Neurol"},{"issue":"Pt 4","key":"pone.0211644.ref008","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1093\/brain\/awr310","article-title":"Epilepsy in patients with a brain tumour: focal epilepsy requires focused treatment","volume":"135","author":"M de Groot","year":"2012","journal-title":"Brain J Neurol"},{"issue":"39","key":"pone.0211644.ref009","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"CJ Phiel","year":"2001","journal-title":"J Biol Chem"},{"issue":"24","key":"pone.0211644.ref010","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"M G\u00f6ttlicher","year":"2001","journal-title":"EMBO J"},{"issue":"7","key":"pone.0211644.ref011","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1200\/JCO.2015.63.6563","article-title":"Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma","volume":"34","author":"C Happold","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"pone.0211644.ref012","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ane.12437","article-title":"Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics","volume":"133","author":"HA Gefroh-Grimes","year":"2016","journal-title":"Acta Neurol Scand"},{"issue":"9","key":"pone.0211644.ref013","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/neuonc\/noq044","article-title":"Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide","volume":"12","author":"GC Bobustuc","year":"2010","journal-title":"Neuro-Oncol"},{"issue":"1","key":"pone.0211644.ref014","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1134\/S1819712416040073","article-title":"Tumor-inhibition effect of levetiracetam in combination with temozolomide in glioblastoma cells","volume":"11","author":"A Marutani","year":"2017","journal-title":"Neurochem J"},{"issue":"17","key":"pone.0211644.ref015","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/cncr.29439","article-title":"Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme","volume":"121","author":"Y-H Kim","year":"2015","journal-title":"Cancer"},{"issue":"8","key":"pone.0211644.ref016","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/glia.21113","article-title":"Glutamate and the biology of gliomas","volume":"59","author":"J de Groot","year":"2011","journal-title":"Glia"},{"issue":"10","key":"pone.0211644.ref017","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nm.2453","article-title":"Glutamate release by primary brain tumors induces epileptic activity","volume":"17","author":"SC Buckingham","year":"2011","journal-title":"Nat Med"},{"issue":"9","key":"pone.0211644.ref018","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1212\/WNL.0b013e318266fa89","article-title":"Glutamate is associated with a higher risk of seizures in patients with gliomas","volume":"79","author":"TI Yuen","year":"2012","journal-title":"Neurology"},{"issue":"19","key":"pone.0211644.ref019","doi-asserted-by":"crossref","first-page":"9463","DOI":"10.1158\/0008-5472.CAN-07-2034","article-title":"Autocrine glutamate signaling promotes glioma cell invasion","volume":"67","author":"SA Lyons","year":"2007","journal-title":"Cancer Res"},{"issue":"30","key":"pone.0211644.ref020","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1523\/JNEUROSCI.2180-07.2007","article-title":"Ca2+-permeable AMPA receptors regulate growth of human glioblastoma via Akt activation","volume":"27","author":"S Ishiuchi","year":"2007","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"8","key":"pone.0211644.ref021","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1158\/1078-0432.CCR-09-3106","article-title":"Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States","volume":"16","author":"SA Grossman","year":"2010","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"7","key":"pone.0211644.ref022","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/cncr.24957","article-title":"Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas","volume":"116","author":"FM Iwamoto","year":"2010","journal-title":"Cancer"},{"issue":"7","key":"pone.0211644.ref023","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1528-1167.2011.03109.x","article-title":"Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy","volume":"52","author":"T Hanada","year":"2011","journal-title":"Epilepsia"},{"issue":"1","key":"pone.0211644.ref024","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist","volume":"56","author":"PN Patsalos","year":"2015","journal-title":"Epilepsia"},{"issue":"5","key":"pone.0211644.ref025","first-page":"286","article-title":"Perampanel in the treatment of a patient with glioblastoma multiforme without IDH1 mutation and without MGMT promotor methylation","volume":"83","author":"J R\u00f6sche","year":"2015","journal-title":"Fortschr Neurol Psychiatr"},{"issue":"7","key":"pone.0211644.ref026","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.21873\/anticanres.12737","article-title":"Seizures and Tumor Progression in Glioma Patients with Uncontrollable Epilepsy Treated with Perampanel","volume":"38","author":"S Izumoto","year":"2018","journal-title":"Anticancer Res"},{"key":"pone.0211644.ref027","article-title":"Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations","author":"C Vecht","year":"2017","journal-title":"J Neurooncol"},{"issue":"8","key":"pone.0211644.ref028","doi-asserted-by":"crossref","first-page":"e71070","DOI":"10.1371\/journal.pone.0071070","article-title":"Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison","volume":"8","author":"CS Mullins","year":"2013","journal-title":"PloS One"},{"issue":"1","key":"pone.0211644.ref029","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"RGW Verhaak","year":"2010","journal-title":"Cancer Cell"},{"issue":"12","key":"pone.0211644.ref030","doi-asserted-by":"crossref","DOI":"10.4172\/1948-5956.1000237","article-title":"A Comprehensive Approach to Patient-individual Glioblastoma Multiforme Model Establishment","volume":"05","author":"CS Mullins","year":"2013","journal-title":"J Cancer Sci Ther"},{"issue":"1","key":"pone.0211644.ref031","first-page":"66","article-title":"Glutamate as chemotactic fuel for diffuse glioma cells: Are they glutamate suckers?","volume":"1846","author":"SAM van Lith","year":"2014","journal-title":"Biochim Biophys Acta BBA\u2014Rev Cancer"},{"issue":"197","key":"pone.0211644.ref032","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ane.12100","article-title":"Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist","author":"MA Rogawski","year":"2013","journal-title":"Acta Neurol Scand Suppl"},{"issue":"2","key":"pone.0211644.ref033","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/A:1022106910017","article-title":"Baseline levels of glucose metabolites, glutamate and glycerol in malignant glioma assessed by stereotactic microdialysis","volume":"61","author":"M Roslin","year":"2003","journal-title":"J Neurooncol"},{"issue":"1","key":"pone.0211644.ref034","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-009-9990-5","article-title":"In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines","volume":"97","author":"HJ Marcus","year":"2010","journal-title":"J Neurooncol"},{"issue":"7","key":"pone.0211644.ref035","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nm.3217","article-title":"BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1","volume":"19","author":"M T\u00f6njes","year":"2013","journal-title":"Nat Med"},{"issue":"10","key":"pone.0211644.ref036","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ebiom.2015.08.026","article-title":"The Human Glioblastoma Cell Culture Resource: Validated Cell Models Representing All Molecular Subtypes","volume":"2","author":"Y Xie","year":"2015","journal-title":"EBioMedicine"},{"issue":"12","key":"pone.0211644.ref037","doi-asserted-by":"crossref","first-page":"14499","DOI":"10.18632\/oncotarget.7391","article-title":"Characterization of novel low passage primary and metastatic colorectal cancer cell lines","volume":"7","author":"A Boot","year":"2016","journal-title":"Oncotarget"},{"key":"pone.0211644.ref038","doi-asserted-by":"crossref","first-page":"568693","DOI":"10.1155\/2014\/568693","article-title":"Biological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines","volume":"2014","author":"F Lange","year":"2014","journal-title":"BioMed Res Int"},{"key":"pone.0211644.ref039","article-title":"The Orally Active Noncompetitive AMPAR Antagonist Perampanel Attenuates Focal Cerebral Ischemia Injury in Rats","author":"H-X Niu","year":"2017","journal-title":"Cell Mol Neurobiol"},{"issue":"12","key":"pone.0211644.ref040","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.4161\/cbt.6.12.4965","article-title":"AMPA antagonists inhibit the extracellular signal regulated kinase pathway and suppress lung cancer growth","volume":"6","author":"A Stepulak","year":"2007","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"pone.0211644.ref041","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.exer.2007.10.011","article-title":"The activation of MEK-ERK1\/2 by glutamate receptor-stimulation is involved in the regulation of RPE proliferation and morphologic transformation","volume":"86","author":"RL Pacheco-Dom\u00ednguez","year":"2008","journal-title":"Exp Eye Res"},{"issue":"2","key":"pone.0211644.ref042","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11060-008-9552-2","article-title":"Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation","volume":"88","author":"JF de Groot","year":"2008","journal-title":"J Neurooncol"},{"issue":"3","key":"pone.0211644.ref043","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11060-016-2056-6","article-title":"The effects of antiepileptic drugs on the growth of glioblastoma cell lines","volume":"127","author":"C-Y Lee","year":"2016","journal-title":"J Neurooncol"},{"issue":"3","key":"pone.0211644.ref044","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ijc.20774","article-title":"Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid","volume":"114","author":"K Camphausen","year":"2005","journal-title":"Int J Cancer"},{"issue":"33","key":"pone.0211644.ref045","doi-asserted-by":"crossref","first-page":"35004","DOI":"10.18632\/oncotarget.5253","article-title":"Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells","volume":"6","author":"D Thotala","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"pone.0211644.ref046","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1159\/000485753","article-title":"Cellular Effects of the Antiepileptic Drug Valproic Acid in Glioblastoma","volume":"44","author":"M Eckert","year":"2017","journal-title":"Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol"},{"key":"pone.0211644.ref047","first-page":"987495","article-title":"Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells","volume":"2012","author":"CH Ryu","year":"2012","journal-title":"J Biomed Biotechnol"},{"issue":"2","key":"pone.0211644.ref048","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11060-014-1713-x","article-title":"The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells","volume":"122","author":"AN Hosein","year":"2015","journal-title":"J Neurooncol"},{"issue":"39","key":"pone.0211644.ref049","doi-asserted-by":"crossref","first-page":"62989","DOI":"10.18632\/oncotarget.11379","article-title":"Molecular dissection of the valproic acid effects on glioma cells","volume":"7","author":"S Hoja","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"pone.0211644.ref050","doi-asserted-by":"crossref","first-page":"14666","DOI":"10.18632\/oncotarget.14716","article-title":"Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression","volume":"8","author":"J-H Tseng","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"pone.0211644.ref051","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/neuonc\/nov125","article-title":"Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questions","volume":"18","author":"S Agnihotri","year":"2016","journal-title":"Neuro-Oncol"},{"key":"pone.0211644.ref052","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fcell.2017.00043","article-title":"Metabolic Reprogramming in Glioma","volume":"5","author":"M Strickland","year":"2017","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"pone.0211644.ref053","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/nm.4418","article-title":"Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma","volume":"23","author":"WX Mai","year":"2017","journal-title":"Nat Med"},{"issue":"7","key":"pone.0211644.ref054","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.cell.2014.11.025","article-title":"Acetate is a bioenergetic substrate for human glioblastoma and brain metastases","volume":"159","author":"T Mashimo","year":"2014","journal-title":"Cell"},{"issue":"31","key":"pone.0211644.ref055","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1523\/JNEUROSCI.5258-04.2005","article-title":"Inhibition of cystine uptake disrupts the growth of primary brain tumors","volume":"25","author":"WJ Chung","year":"2005","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"6","key":"pone.0211644.ref056","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nm1772","article-title":"Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema","volume":"14","author":"NE Savaskan","year":"2008","journal-title":"Nat Med"},{"issue":"24","key":"pone.0211644.ref057","doi-asserted-by":"crossref","first-page":"10767","DOI":"10.1523\/JNEUROSCI.19-24-10767.1999","article-title":"Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange","volume":"19","author":"ZC Ye","year":"1999","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"289","key":"pone.0211644.ref058","doi-asserted-by":"crossref","first-page":"289ra86","DOI":"10.1126\/scitranslmed.aaa8103","article-title":"SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma","volume":"7","author":"SM Robert","year":"2015","journal-title":"Sci Transl Med"},{"issue":"1","key":"pone.0211644.ref059","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11060-018-2785-9","article-title":"High expression of cystine-glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma","volume":"138","author":"MF S\u00f8rensen","year":"2018","journal-title":"J Neurooncol"},{"issue":"5","key":"pone.0211644.ref060","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1158\/0008-5472.CAN-04-3626","article-title":"The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo","volume":"65","author":"JF de Groot","year":"2005","journal-title":"Cancer Res"},{"key":"pone.0211644.ref061","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-3-319-08894-5_2","article-title":"Glutamate metabolism in the brain focusing on astrocytes","volume":"11","author":"A Schousboe","year":"2014","journal-title":"Adv Neurobiol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0211644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T20:31:37Z","timestamp":1706905897000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0211644"}},"subtitle":[],"editor":[{"given":"Seok-Geun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,2,4]]},"references-count":61,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0211644","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,4]]}}}